Generic name: INFLUENZA A VIRUS A/BRISBANE/59/2007(H1N1) HEMAGGLUTININ ANTIGEN (UV,FORMALDEHYDE INACTIVATED) 15ug in 0.5mL, INFLUENZA A VIRUS A/URUGUAY/716/2007(H3N2) HEMAGGLUTININ ANTIGEN (UV,FORMALDEHYDE INACTIVATED) 15ug in 0.5mL, INFLUENZA B VIRUS B/BRISBANE/60/2008 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15ug in 0.5mL
Dosage form: injection, suspension
Medically reviewed by Drugs.com. Last updated on July 13, 2020.
Preparation for Administration
Shake the multi-dose vial vigorously each time before withdrawing a dose of vaccine. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.
Between uses, return the multi-dose vial to the recommended storage conditions, between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen. Once entered, a multi-dose vial, and any residual contents, should be discarded after 28 days.
It is recommended that small syringes (0.5-mL or 1-mL) be used to minimize any product loss.
Recommended Dose and Schedule
FLULAVAL should be administered as a single 0.5-mL injection by the intramuscular route preferably in the region of the deltoid muscle of the upper arm.
The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk. A needle length of ≥1 inch is preferred because needles <1 inch might be of insufficient length to penetrate muscle tissue in certain adults.
Do not administer this product intravenously, intradermally or subcutaneously.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about FluLaval (influenza virus vaccine, inactivated)
- Side Effects
- During Pregnancy
- Drug Interactions
- Drug class: viral vaccines
- FDA Alerts (1)
- FDA Approval History